Brief: MediciNova Announces Initiation Of Phase 2 Trial of MN-001 (Tipelukast) in NAFLD with Type 2 Diabetes Mellitus and Hypertriglyceridemia
26/07/2022 11:38
July 26 (Reuters) - MediciNova Inc MNOV.O :
* MEDICINOVA ANNOUNCES INITIATION OF A PHASE 2 TRIAL OF
MN-001
(TIPELUKAST) IN NAFLD WITH TYPE 2 DIABETES MELLITUS AND
HYPERTRIGLYCERIDEMIA
Source text for Eikon: ID:nGNXm5CLt
Further company coverage: MNOV.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicinova
See all newsBrief: 3D Investment Partners Cuts Stake In Medicinova To 9.88% From 11.22%, Filing Shows
US STOCKS ON THE MOVE-Mirum Pharmaceuticals, Meta, Boeing
U.S. STOCKS ON THE MOVE-Royal Caribbean Cruises, SpaceX
MediciNova falls as fatty liver drug misses significance on blood-fat reduction
US STOCKS ON THE MOVE-WhiteHawk, Nvidia, Snowflake